查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143591

醫藥CDMO和契約製造服務市場：全球市場預測，2026-2032年

Pharmaceutical CDMO & Contract Manufacturing Services Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫藥 CDMO 和契約製造服務市場將成長至 1,953.8 億美元，複合年成長率為 7.33%。

主要市場統計數據
基準年 2025 1190.1億美元
預計年份：2026年 1282億美元
預測年份 2032 1953.8億美元
複合年成長率 (%) 7.33%

醫藥CDMO服務：概述

合約研發生產機構 (CDMO) 為製藥研發公司提供製程開發、分析服務、臨床試驗藥物供應、商業化生產、包裝及相關品管活動等方面的支援。該市場的發展受到技術複雜性不斷提高、監管要求日益嚴格、外包策略日益普及以及對穩健供應鏈網路的需求等因素的影響。生物製藥、無菌製劑、先進醫療技術、複雜口服製劑和專業化生產技術尤其影響市場需求。

外包、專業化和供應鏈彈性正在重塑市場結構。

製藥公司擴大利用外部合作夥伴，以發揮其專業設施、技術專長、靈活的生產能力和成熟的品質系統。隨著企業減少內部資本投入並加速從研發到商業化的過渡，外包決策也變得更有策略性。同時，供應鏈中斷、地緣政治不確定性、原料短缺和運輸限制正在推動多地點採購、地域多角化、更嚴格的供應商資格篩選以及更嚴格的業務永續營運計劃。監管力度的加強凸顯了資料完整性、製程驗證、污染控制、可追溯性和一致的技術轉移的重要性。

人工智慧（AI）增強了研發、品質和製造方面的決策能力。

人工智慧 (AI) 透過製程最佳化、預測性維護、偏差調查、分析資料審核、製劑開發支援、需求計劃和文件工作流程等方式，為製藥合約研發生產企業 (CDMO) 的營運做出貢獻。機器學習工具可以幫助識別製程變異並確定調查優先級，而生成式系統則可以在受控管治下加速技術文件的撰寫和知識搜尋。人工智慧的應用仍然依賴檢驗的數據、模型的可解釋性、網路安全、人工監督以及對適用的品質和隱私要求的遵守。經營團隊應將人工智慧視為實驗室、生產和品質系統功能的補充，而不是專家判斷的無監督替代品。

區域洞察：六大市場的能力與政策環境差異

北美擁有生物製藥領域的深厚專業知識、先進的研發基礎設施以及對複雜無菌生產的強勁需求等優勢，但也面臨嚴格的合規、勞動力和營運要求。歐洲擁有成熟的品質系統和專業的生產能力，並且越來越重視永續性、供應穩定性和監管協調。亞太地區擁有廣泛的生產基地、不斷增強的科研能力以及日益成長的國內藥品需求，但申辦方需要評估品質一致性、技術轉移準備以及地緣政治風險。拉丁美洲受益於當地醫療保健需求和區域生產需求，但基礎設施、監管趨同以及專業技術的取得途徑因國家而異。中東地區注重醫療保健在地化和產業多元化，為特定的生產和包裝能力創造了機會。非洲在藥品取得和本地生產優先事項方面具有長期潛力，但基礎設施、資金籌措、技術能力和監管成熟度仍然存在差異。

集團洞察：貿易、監管與產業政策塑造合作

東協市場在區域供應鏈多元化方面的重要性日益凸顯，但贊助企業必須考慮監管實施、技術基礎設施和跨境物流的差異。金磚國家擁有龐大的藥品需求和生產意願，但核准流程、智慧財產權環境和貿易條款因國家而異。歐盟受益於統一的法規結構，但各國在產業生態系統和商業環境方面仍有顯著差異。七國集團（G7）國家擁有先進的科技、完善的品管系統和成熟的贊助網路，但在成本和合規方面也面臨相對嚴峻的挑戰。海灣合作理事會（GCC）市場優先考慮對醫療保健韌性、在地化和生命科學能力的投資，而其落實取決於技能人才的培養和技術夥伴關係。北約成員國受到通用安全考量和供應鏈韌性優先事項的影響，但各國和各地區的藥品生產政策仍有差異。

針對特定國家的見解：為了發揮當地優勢，合作夥伴的選擇需要根據具體情況而定。

澳洲擁有強大的研發能力和進入監管市場的管道，但地理距離使得物流和供應連續性至關重要。巴西擁有大規模的國內醫療保健系統，優先發展本地生產，但監管環境較為複雜。加拿大提供深入的研發和完善的品管，其規模和跨國合作往往會影響採購決策。中國擁有廣泛的藥品生產能力和供應商基礎，但贊助商需要評估相關法規、數據、智慧財產權和地緣政治因素。法國、德國、義大利和西班牙提供歐洲特有的專業知識和進入歐盟框架的管道，但各國在勞動力、基礎設施和產業重點領域存在差異。印度在各種製劑、活性藥物成分和研發方面擁有豐富的專業知識，但需要仔細評估其設施品質、文件記錄和檢查準備。日本以高標準的製藥水平和技術先進性著稱，但市場准入和品質要求也很高。韓國已建立起強大的生物製藥和生產能力，尤其擅長複雜產品的生產。墨西哥支持區域供應鏈和近岸外包策略，但其各供應商的能力和合規性存在差異。俄羅斯的角色受到國內生產優先事項、制裁、貿易限制以及部分國際原料取得受限等因素的影響。英國在生命科學領域擁有強大的專業知識和監管合規能力，但專案發起人必須考慮英國脫歐後的安排以及跨境供應鏈的調整。美國仍然是創新、臨床開發和受監管生產的重要中心，擁有嚴格的合規和營運要求。

製藥業領導者的優先行動

領導者應根據​​治療領域、研發階段、製程複雜性和監管風險對合約研發開發機構 (CDMO) 合作夥伴進行分類，而不僅依賴產能。合格評估應驗證品質系統的成熟度、檢查歷史、資料完整性、變更管理規格、技術轉移記錄、污染檢驗、人員配備和業務永續營運能力。合約應明確界定偏差責任、等效性、智慧財產權、網路安全、原料變更、審計權以及與監管機構溝通等方面的責任。企業應在實際可行的範圍內為關鍵原料和營運建立雙重來源或合格的備用方案。人工智慧投資應從高價值、可管理的應用案例入手，並包含檢驗、存取控制、審計追蹤和人工審核。區域決策應權衡技術能力、整體供應鏈風險、永續性要求以及與患者和終端市場的接近性。

調查方法：對特定市場進行結構化解讀

本執行摘要依據醫藥CDMO和契約製造服務的定義範圍，依產業結構、技術、地區、經濟集團和特定國家的商業環境對研究結果進行分類。檢驗重點關注可驗證的策略促進因素，包括外包現狀、生產複雜性、法規、供應鏈韌性、數位化和產業政策。區域、集團和國家的具體觀察結果以定性比較的形式呈現，而非數值估算。本摘要不包含市場規模估算、市佔率計算、預測或未經證實的公司特定聲明。在實踐中，決策者應根據最新的監管文件、檢查記錄、供應商審計、技術評估和當地政策發展來檢驗結論的有效性。

結論：嚴格的夥伴篩選是決定CDMO優劣的關鍵。

醫藥CDMO服務正變得日益專業化、技術驅動，並對產品持續生產具有重要的戰略意義。成功的關鍵在於為每個專案合理整合合適的技術平台、品質文化、規模化生產經驗、地理覆蓋範圍和韌性。區域和國家層面的能力不可互換，即使集團層級達成一致也無法消除當地監管和營運的差異。業界領導者若能將嚴格的合作夥伴管治、多元化的供應計劃、負責任的AI應用以及早期技術合作相結合，將更有能力應對從研發到商業化生產過程中的各種複雜挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 醫藥CDMO和契約製造服務市場：依服務類型分類

  • 分析服務
    • GMP偵測
    • 分析方法的開發
    • 穩定性測試
  • 藥物製劑
    • 填充和精加工
    • 配方
  • 原料藥
  • 包裝和標籤
  • 臨床前服務

第8章：藥品CDMO和契約製造服務市場：依分子類別分類

  • 生物製劑
    • 單株抗體
    • 重組蛋白
    • 疫苗
  • 細胞和基因治療
    • 細胞療法
    • 基因治療
  • 寡核苷酸
  • 胜肽
  • 低分子

第9章：醫藥CDMO和契約製造服務市場：依技術平台分類

  • 注射藥物
    • 液體
    • 冷凍乾燥製劑
  • 脂質奈米顆粒
  • 固態劑型
  • 無菌
    • 預填充式注射器
    • 管瓶

第10章：醫藥CDMO和契約製造服務市場：依研發階段分類

  • I期臨床試驗
  • 二期臨床試驗
  • III期臨床試驗
  • 商業的

第11章：醫藥CDMO和契約製造服務市場：依治療領域分類

  • 心血管系統
  • 中樞神經系統（CNS）
  • 感染疾病
  • 腫瘤學
    • 血液學
    • 固體癌
  • 呼吸系統

第12章 醫藥CDMO和契約製造服務市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：醫藥CDMO和契約製造服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 醫藥CDMO和契約製造服務市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Aenova Holding GmbH
  • AGC Biologics Inc
  • Alcami Corporation
  • Asymchem Laboratories（Tianjin）Co Ltd
  • Boehringer Ingelheim GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Divi's Laboratories Limited
  • Eurofins Scientific SE
  • Evonik Industries AG
  • FAMAR Health Care Services AG
  • Hovione LLC
  • Lonza Group AG
  • Metrics Contract Services LLC
  • Neuland Laboratories Limited
  • Piramal Pharma Ltd
  • Porton Pharma Solutions Limited
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Siegfried Holding AG
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.

第17章 主要專家

Product Code: MRR-9C4233EE7D74

The Pharmaceutical CDMO & Contract Manufacturing Services Market is projected to grow by USD 195.38 billion at a CAGR of 7.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 119.01 billion
Estimated Year [2026] USD 128.20 billion
Forecast Year [2032] USD 195.38 billion
CAGR (%) 7.33%

Pharmaceutical CDMO Services: Executive Overview

Pharmaceutical contract development and manufacturing organizations (CDMOs) support drug developers across process development, analytical services, clinical supply, commercial production, packaging, and related quality activities. The market is shaped by rising technical complexity, tighter regulatory expectations, outsourcing strategies, and the need for resilient supply networks. Demand is particularly influenced by biologics, sterile products, advanced therapies, complex oral formulations, and specialized manufacturing technologies.

Outsourcing, Specialization, and Supply Resilience Reshape the Landscape

Pharmaceutical manufacturers are increasingly using external partners to access specialized facilities, technical expertise, flexible capacity, and established quality systems. Outsourcing decisions are also becoming more strategic as sponsors seek to reduce internal capital requirements and accelerate transitions from development to commercial production. At the same time, supply-chain disruptions, geopolitical uncertainty, input shortages, and transportation constraints are encouraging multi-site sourcing, regionalization, stronger supplier qualification, and more rigorous business-continuity planning. Regulatory scrutiny is raising the importance of data integrity, process validation, contamination control, traceability, and consistent technology transfer.

Artificial Intelligence Strengthens Development, Quality, and Manufacturing Decisions

Artificial intelligence is contributing to pharmaceutical CDMO operations through process optimization, predictive maintenance, deviation investigation, analytical data review, formulation support, demand planning, and document workflows. Machine-learning tools can help identify process variability and prioritize investigations, while generative systems may accelerate technical writing and knowledge retrieval under controlled governance. Adoption remains dependent on validated data, model explainability, cybersecurity, human oversight, and compliance with applicable quality and privacy requirements. Leaders should treat AI as an augmenting capability integrated with laboratory, manufacturing, and quality systems rather than as an unsupervised replacement for expert judgment.

Regional Insights: Capabilities and Policy Environments Differ Across Six Markets

North America benefits from deep biopharmaceutical expertise, advanced development infrastructure, and strong demand for complex and sterile manufacturing, while also facing high compliance, labor, and operating requirements. Europe combines mature quality systems and specialized manufacturing capabilities with heightened attention to sustainability, supply security, and regulatory harmonization. Asia-Pacific offers broad manufacturing depth, expanding scientific capabilities, and growing domestic pharmaceutical demand, although sponsors must evaluate quality consistency, technology-transfer readiness, and geopolitical exposure. Latin America is supported by local healthcare demand and regional production needs, with infrastructure, regulatory convergence, and access to specialized technologies varying by country. The Middle East is emphasizing healthcare localization and industrial diversification, creating opportunities for selected production and packaging capabilities. Africa presents longer-term potential linked to medicine access and local manufacturing priorities, but infrastructure, financing, technical capacity, and regulatory maturity remain uneven.

Group Insights: Trade, Regulation, and Industrial Policy Shape Collaboration

ASEAN markets are increasingly relevant to regional supply diversification, but sponsors must account for differences in regulatory implementation, technical infrastructure, and cross-border logistics. BRICS economies combine substantial pharmaceutical demand and manufacturing ambitions with varied approval pathways, intellectual-property environments, and trade conditions. The European Union benefits from a harmonized regulatory framework while retaining meaningful national differences in industrial ecosystems and operating conditions. G7 countries provide advanced science, sophisticated quality oversight, and established sponsor networks, alongside comparatively demanding cost and compliance environments. GCC markets are prioritizing healthcare resilience, localization, and investment in life-science capabilities, with execution depending on skilled workforce development and technology partnerships. NATO members are affected by shared security considerations and supply-chain resilience priorities, though pharmaceutical manufacturing policies remain nationally and regionally differentiated.

Country Insights: Local Strengths Require Tailored Partner Evaluation

Australia offers strong research capabilities and regulated-market access, while geographic distance makes logistics and supply continuity important. Brazil combines a large domestic healthcare system with local-production priorities and regulatory complexity. Canada provides research depth and established quality oversight, with scale and cross-border coordination often influencing sourcing decisions. China has extensive pharmaceutical manufacturing capacity and a broad supplier base, while sponsors must assess regulatory, data, intellectual-property, and geopolitical considerations. France, Germany, Italy, and Spain contribute specialized European capabilities and access to the European Union framework, with national differences in workforce, infrastructure, and industrial focus. India offers broad formulation, active pharmaceutical ingredient, and development expertise, requiring careful evaluation of site quality, documentation, and inspection readiness. Japan is distinguished by advanced pharmaceutical standards and technical sophistication, alongside demanding market-entry and quality expectations. South Korea has developed strong biopharmaceutical and manufacturing capabilities, particularly for complex products. Mexico supports regional supply chains and nearshoring strategies, with site capability and regulatory readiness varying across providers. Russia's role is influenced by domestic-production priorities, sanctions, trade restrictions, and limited access to some international inputs. The United Kingdom retains strong life-science expertise and regulatory capability, while sponsors must consider post-EU arrangements and cross-border supply coordination. The United States remains a major center for innovation, clinical development, and regulated manufacturing, with stringent compliance and operating requirements.

Action Priorities for Pharmaceutical Industry Leaders

Leaders should segment CDMO partners by modality, development stage, process complexity, and regulatory risk rather than relying on capacity alone. Qualification should test quality-system maturity, inspection history, data integrity, change-control discipline, technology-transfer performance, contamination controls, staffing, and business-continuity capabilities. Contracts should define responsibilities for deviations, comparability, intellectual property, cybersecurity, raw-material changes, audit rights, and regulatory communication. Companies should build dual-sourcing or qualified-backup options for critical materials and operations where practical. AI investments should begin with high-value, governable use cases and include validation, access controls, audit trails, and human review. Regional decisions should balance technical capability, total supply-chain exposure, sustainability requirements, and proximity to patients or final markets.

Research Methodology: Structured Interpretation of the Defined Market

This executive summary uses the defined pharmaceutical CDMO and contract manufacturing services scope and organizes findings across industry structure, technology, geography, economic groupings, and national operating environments. The assessment emphasizes verifiable strategic drivers, including outsourcing practices, manufacturing complexity, regulation, supply-chain resilience, digitalization, and industrial policy. Regional, group, and country observations are presented as qualitative comparisons rather than numerical estimates. No market sizing, market-share calculations, forecasts, or unsupported company-specific claims are included. In practical application, decision-makers should validate conclusions against current regulatory publications, inspection records, supplier audits, technical assessments, and local policy developments.

Conclusion: Disciplined Partner Selection Will Define CDMO Advantage

Pharmaceutical CDMO services are becoming more specialized, technology-enabled, and strategically important to product continuity. Success will depend on matching each program with the right technical platform, quality culture, scale-up experience, geographic footprint, and resilience profile. Regional and country capabilities are not interchangeable, and group-level alignment does not remove local regulatory or operational differences. Industry leaders that combine rigorous partner governance, diversified supply planning, responsible AI adoption, and early technical collaboration will be better positioned to manage complexity from development through commercial manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmaceutical CDMO & Contract Manufacturing Services Market, by Service Type

  • 7.1. Introduction
  • 7.2. Analytical Services
    • 7.2.1. Gmp Testing
    • 7.2.2. Method Development
    • 7.2.3. Stability Testing
  • 7.3. Drug Product
    • 7.3.1. Fill Finish
    • 7.3.2. Formulation
  • 7.4. Drug Substance
  • 7.5. Packaging And Labelling
  • 7.6. Preclinical Services

8. Pharmaceutical CDMO & Contract Manufacturing Services Market, by Molecule Class

  • 8.1. Introduction
  • 8.2. Biologics
    • 8.2.1. Monoclonal Antibodies
    • 8.2.2. Recombinant Proteins
    • 8.2.3. Vaccines
  • 8.3. Cell And Gene Therapy
    • 8.3.1. Cell Therapy
    • 8.3.2. Gene Therapy
  • 8.4. Oligonucleotides
  • 8.5. Peptides
  • 8.6. Small Molecule

9. Pharmaceutical CDMO & Contract Manufacturing Services Market, by Technology Platform

  • 9.1. Introduction
  • 9.2. Injectable
    • 9.2.1. Liquid
    • 9.2.2. Lyophilized
  • 9.3. Lipid Nanoparticle
  • 9.4. Solid Dosage
  • 9.5. Sterile
    • 9.5.1. Prefilled Syringe
    • 9.5.2. Vial

10. Pharmaceutical CDMO & Contract Manufacturing Services Market, by Development Phase

  • 10.1. Introduction
  • 10.2. Clinical Phase I
  • 10.3. Clinical Phase Ii
  • 10.4. Clinical Phase Iii
  • 10.5. Commercial

11. Pharmaceutical CDMO & Contract Manufacturing Services Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cardiovascular
  • 11.3. Cns
  • 11.4. Infectious Diseases
  • 11.5. Oncology
    • 11.5.1. Hematological
    • 11.5.2. Solid Tumors
  • 11.6. Respiratory

12. Pharmaceutical CDMO & Contract Manufacturing Services Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Pharmaceutical CDMO & Contract Manufacturing Services Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Pharmaceutical CDMO & Contract Manufacturing Services Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Aenova Holding GmbH
  • 16.2. AGC Biologics Inc
  • 16.3. Alcami Corporation
  • 16.4. Asymchem Laboratories (Tianjin) Co Ltd
  • 16.5. Boehringer Ingelheim GmbH
  • 16.6. Cambrex Corporation
  • 16.7. Catalent, Inc.
  • 16.8. Divi's Laboratories Limited
  • 16.9. Eurofins Scientific SE
  • 16.10. Evonik Industries AG
  • 16.11. FAMAR Health Care Services AG
  • 16.12. Hovione LLC
  • 16.13. Lonza Group AG
  • 16.14. Metrics Contract Services LLC
  • 16.15. Neuland Laboratories Limited
  • 16.16. Piramal Pharma Ltd
  • 16.17. Porton Pharma Solutions Limited
  • 16.18. Recipharm AB
  • 16.19. Samsung Biologics Co., Ltd.
  • 16.20. Siegfried Holding AG
  • 16.21. Syngene International Limited
  • 16.22. Thermo Fisher Scientific Inc.
  • 16.23. WuXi AppTec Co., Ltd.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Pharmaceutical CDMO & Contract Manufacturing Services Market, Years Considered for the Study
  • FIGURE 2. Global Pharmaceutical CDMO & Contract Manufacturing Services Market, Research Design
  • FIGURE 3. Global Pharmaceutical CDMO & Contract Manufacturing Services Market, Research Framework
  • FIGURE 4. Global Pharmaceutical CDMO & Contract Manufacturing Services Market, Data Triangulation
  • FIGURE 5. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2025 vs 2032 (%)
  • FIGURE 9. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2025 vs 2032 (%)
  • FIGURE 11. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2025 vs 2032 (%)
  • FIGURE 13. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2025 vs 2032 (%)
  • FIGURE 15. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Segmentation & Coverage
  • TABLE 2. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 4. Global Analytical Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Analytical Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Analytical Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Gmp Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Gmp Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Gmp Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Method Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Method Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Method Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Stability Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Stability Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Stability Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Drug Product Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Drug Product Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Drug Product Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Fill Finish Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Fill Finish Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Fill Finish Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Formulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Formulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Formulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Drug Substance Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Drug Substance Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Drug Substance Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Packaging And Labelling Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Packaging And Labelling Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Packaging And Labelling Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Preclinical Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Preclinical Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Preclinical Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 35. Global Biologics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global Biologics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global Biologics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global Monoclonal Antibodies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Monoclonal Antibodies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Monoclonal Antibodies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Recombinant Proteins Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Recombinant Proteins Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Recombinant Proteins Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Cell And Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Cell And Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Cell And Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Peptides Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Peptides Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Peptides Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 66. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Liquid Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Liquid Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Liquid Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Lyophilized Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Lyophilized Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Lyophilized Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Lipid Nanoparticle Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Lipid Nanoparticle Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Lipid Nanoparticle Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Solid Dosage Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Solid Dosage Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Solid Dosage Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Sterile Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Sterile Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Sterile Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 91. Global Clinical Phase I Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Global Clinical Phase I Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 93. Global Clinical Phase I Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 94. Global Clinical Phase Ii Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 95. Global Clinical Phase Ii Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 96. Global Clinical Phase Ii Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 97. Global Clinical Phase Iii Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Global Clinical Phase Iii Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 99. Global Clinical Phase Iii Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 100. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 102. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 103. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 104. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 107. Global Cns Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Global Cns Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. Global Cns Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 110. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 113. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 115. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 116. Global Hematological Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 117. Global Hematological Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 118. Global Hematological Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 119. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 120. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 121. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 122. Global Respiratory Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 123. Global Respiratory Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 124. Global Respiratory Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 125. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 126. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 127. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 128. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 129. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 130. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 131. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 132. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 133. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 134. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 135. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 136. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 137. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 138. Asia-Pacific Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 139. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 140. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 141. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 142. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 143. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 144. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 145. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 146. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 147. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 148. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 149. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 150. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 151. North America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 152. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 153. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 154. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 155. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 156. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 157. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 158. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 159. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 160. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 161. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 162. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 163. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 164. Latin America Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 165. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 166. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 167. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 168. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 169. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 170. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 171. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 172. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 173. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 174. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 175. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 176. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 177. Europe Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 178. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 179. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 180. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 181. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 182. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 183. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 184. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 185. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 186. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 187. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 188. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 189. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 190. Middle East Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 191. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 192. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 193. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 194. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 195. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 196. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 197. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 198. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 199. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 200. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 201. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 202. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 203. Africa Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 204. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 205. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 206. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 207. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 208. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 209. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 210. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 211. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 212. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 213. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 214. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 215. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 216. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 217. ASEAN Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 218. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 219. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 220. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 221. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 222. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 223. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 224. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 225. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 226. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 227. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 228. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 229. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 230. GCC Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 231. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 232. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 233. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 234. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 235. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 236. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 237. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 238. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 239. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 240. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 241. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 242. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 243. European Union Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 244. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 245. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 246. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 247. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 248. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 249. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 250. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 251. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 252. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 253. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 254. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 255. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 256. BRICS Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 257. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 258. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 259. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 260. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 261. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 262. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 263. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 264. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 265. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 266. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 267. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 268. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 269. G7 Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 270. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 271. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 272. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 273. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 274. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 275. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 276. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 277. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 278. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 279. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 280. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 281. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 282. NATO Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 283. Global Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 284. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, 2017-2032 (USD Million)
  • TABLE 285. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 286. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 287. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Drug Product, 2017-2032 (USD Million)
  • TABLE 288. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 289. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Biologics, 2017-2032 (USD Million)
  • TABLE 290. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Cell And Gene Therapy, 2017-2032 (USD Million)
  • TABLE 291. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 292. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 293. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Sterile, 2017-2032 (USD Million)
  • TABLE 294. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Development Phase, 2017-2032 (USD Million)
  • TABLE 295. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 296. United States Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 297. Canada Pharmaceutical CDMO & Contract Manufacturing Services Market Size, 2017-2032 (USD Million)
  • TABLE 298. Canada Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 299. Canada Pharmaceutical CDMO & Contract Manufacturing Services Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 300. Canada Pharmaceutical CDMO & C